DLL1 and cancer: In summarizing our study, CD133 was exclusively expressed in cancer cells compared to stromal and immune cells and was associated with other CSC markers (CD24, NOTCH1, DLL1, and ALDH1A1), as well as enriched WNT/β-Catenin, Hedgehog, and NOTCH signaling, validating CD133 as a CSC marker.